Tirzepatide: How the Dual Agonist Changed the Field

When tirzepatide’s weight-loss results landed, they didn’t just extend the GLP-1 story; they reset what the field considered possible with a drug. Average weight reductions reached into territory previously associated more with bariatric surgery than with medication. The reason it was grouped loosely under “GLP-1 drugs” but behaves differently comes down to its design: tirzepatide hits two incretin receptors at once, not one.

What “dual agonist” means

Most drugs that defined the early GLP-1 era act on a single target: the GLP-1 receptor. Tirzepatide adds a second. It’s a dual agonist of both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Both are gut-derived incretin hormones involved in regulating insulin, appetite, and metabolism.

The working hypothesis is that engaging both pathways produces effects greater than acting on either alone. GLP-1 agonism reduces appetite, slows gastric emptying, and improves glucose-dependent insulin secretion; adding GIP agonism appears to contribute additional metabolic and appetite effects. Fruit, oranges, sliced — illustrating Tirzepatide: How the Dual Agonist Changed the Field

The precise reason GIP agonism adds so much remains an active scientific question; the biology of GIP is genuinely subtle. What’s not in doubt is that the dual-target drug produced larger average weight loss than single-target predecessors.

Why the numbers reset expectations

Tray, breakfast, muesli — illustrating Tirzepatide: How the Dual Agonist Changed the Field

In SURMOUNT-1, the pivotal obesity trial published in the New England Journal of Medicine in 2022, 2,539 adults with obesity or overweight were randomized across three doses and placebo for 72 weeks. The dose-dependent results were striking:

Treatment	Average weight loss at 72 weeks
Tirzepatide 5 mg	16.0%
Tirzepatide 10 mg	21.4%
Tirzepatide 15 mg	22.5%
Placebo	2.4%

For a once-weekly injection, that was a genuine step change, not an incremental improvement. What makes the effect notable in context:

Magnitude. Average reductions exceeded earlier-generation agents by a meaningful margin, prompting comparisons to surgical outcomes at the top doses.
Glycemic power. In type 2 diabetes, tirzepatide produced strong improvements in blood-sugar control alongside weight loss.
Same class, bigger lever. It works through familiar incretin biology, but pulls a second lever rather than just a stronger version of the first.

The trade-offs that come with it

None of this makes it free of cost. Tirzepatide shares the class’s gastrointestinal side-effect profile: nausea, vomiting, diarrhea, and constipation, usually worst during dose escalation and often improving over time. As with the rest of the category, weight tends to return after stopping, which frames it as an ongoing treatment rather than a course.

The takeaway

Tirzepatide changed the field by demonstrating that targeting two incretin receptors at once could produce weight loss earlier GLP-1 drugs couldn’t match: up to 22.5% on average in SURMOUNT-1, narrowing for some patients the gap between medication and surgery. The mechanism is understood well enough to explain that it works, even if exactly why GIP adds so much is still being studied. Impressive and incomplete, both at once.